Mirtazapine
| Mirtazapine | |
|---|---|
| Salts [] | |
|---|---|
| Mirtazapine hemihydrate | |
| Mirtazapine hydrobromide | |
| Mirtazapine hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 265.35 g/mol [1] |
| Melting point | 114-116 °C [1] |
| Boiling point | 432.4 [1] |
| Solubility | slightly soluble in water [1] |
| Predicted LogP | 3.3 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C17H19N3 |
| IUPAC name | 5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene |
| SMILES | CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4 |
| InChI | InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3 |
| InChIKey | RONZAEMNMFQXRA-UHFFFAOYSA-N |
| CAS number | 85650-52-8 |
| UNII | A051Q2099Q |
| PubChem CID | 4205 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 20–40 hours |
| Metabolism | Liver (CYP1A2, CYP2D6, CYP3A4) |
| Excretion | Urine: 75%, Feces: 15% |
| Routes of administration | By mouth, topical |
| Toxicity [] | |
|---|---|
| LD50 | Mice: - oral: 600-720mg/kg [1] |
Mirtazapine (also known as Remeron, Mepirzepine, 6-Azamianserin, Remergon, Zispin, Promyrtil, Remergil, Rexer, Avanza or Norset) is a antidepressant and depressant substance of the phenethylamine class.
Chemistry
Salts []
Stereochemistry []
Mirtazapine is a racemic mixture of the enantiomers (optical activity ( + / - )).
| Stereoisomerism |
|---|
| Stereoisomers from PubChem |
Druglikeness
Lipinski's rule of five
Mirtazapine matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- psychoanaleptics (N06)
- antidepressants (N06A)
- other antidepressants (N06AX)
- (N06AX11)
- mirtazapine (N06AX11)
MeSH Classification
- antidepressive agents (M0001384)
- histamine h1 antagonists (M0010395)
- anti-anxiety agents (M0021771)
- adrenergic alpha-2 receptor antagonists (M0543997)
- serotonin 5-ht2 receptor antagonists (M0544718)
- serotonin 5-ht3 receptor antagonists (M0544719)
Mechanism of action []
**Summary** The mechanism of action of mirtazapine is not fully understood but may be explained by its effects on central adrenergic and serotonergic activity. This drug exhibits a fast onset of action, a high level of response, a manageable side-effect profile, and dual noradrenergic and serotonergic effects that are unique from the effects of other antidepressants. **Effects on various receptors** It has been shown that both noradrenergic and serotonergic activity increase following mirtazapine administration. The results of these studies demonstrate mirtazapine exerts antagonist activity at presynaptic α2-adrenergic inhibitory autoreceptors and heteroreceptors in the central nervous system. This is thought to lead to enhanced noradrenergic and serotonergic activity, which are known to improve the symptoms of depression and form the basis of antidepressant therapy. Mirtazapine is a strong antagonist of serotonin 5-HT2 and 5-HT3 receptors. It has not been found to bind significantly to the serotonin 5-HT1A and 5-HT1B receptors but indirectly increases 5-HT1A transmission. In addition to the above effects, mirtazapine is a peripheral α1-adrenergic antagonist. This action may explain episodes of orthostatic hypotension that have been reported after mirtazapine use. Mirtazapine is a potent histamine (H1) receptor antagonist, which may contribute to its powerful sedating effects. The pain-relieving effects of mirtazapine may be explained by its effects on opioid receptors. [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| CYP3A4 | metabolism / inhibition / induction | 252 (3 contraindicated) |
|---|---|---|
| CYP2D6 | inhibition / metabolism / induction | 58 (5 contraindicated) |
| CYP1A2 | metabolism / inhibition / induction | 22 (4 contraindicated) |
| ADRA2A | shared target | 3 (1 contraindicated) |
| ADRA2B | shared target | 3 (1 contraindicated) |
| ADRA2C | shared target | 3 (1 contraindicated) |
| HTR2A | shared target | 1 |
Medical side effects []
328 side effects listed on drug labels in SIDER 4.1 (mirtazapine).
- Somnolence
- Drowsiness
- Dry mouth
- Increased appetite
- Constipation
- Weight increased
- Asthenia
- Fatigue
- Dizziness
- Syncope
- Acute abdomen
- Abdominal pain
- Gastrointestinal pain
- Amnesia
- Decreased appetite
- Anxiety
- Arthralgia
- Musculoskeletal discomfort
- Myalgia
- Dermatitis
- Rash
- Hypertension
- Hypoaesthesia
- Influenza
- Paraesthesia
- Pruritus
- Sinusitis
- Thirst
- Urinary tract infection
- Vertigo
- Apathy
- Flat affect
- Hypokinesia
- Malaise
- Discomfort
- Feeling abnormal
- Confusional state
- Ill-defined disorder
- Muscle twitching
- Agitation
- Hyperkinesia
- Cough
- Muscular weakness
- Abnormal dreams
- Vivid dreams
- Thinking abnormal
- Mental disability
- Cerebration impaired
- Back pain
- Tremor
- Pollakiuria
- Micturition urgency
- Oedema peripheral
- Ankle edema
- Dyspnoea
- Oedema
- Alopecia
- Amenorrhoea
- Angina pectoris
- Arthritis
- Asthma
- Ataxia
- Bronchitis
- Neck pain
- Cholecystitis
- Colitis
- Conjunctivitis
- Cystitis
- Bladder pain
- Cystitis noninfective
- Deafness
- Dehydration
- Delirium
- Delusion
- Depersonalisation
- Dermatitis exfoliative
- Dysarthria
- Osteoarthritis
- Arthropathy
- Dyskinesia
- Movement disorder
- Dysmenorrhoea
- Dysuria
- Ear pain
- Epistaxis
- Eructation
- Extrapyramidal disorder
- Body temperature increased
- Gingival bleeding
- Glaucoma
- Angle closure glaucoma
- Glossitis
- Hallucination
- Haematuria
- Herpes simplex
- Hostility
- Hypotension
- Libido increased
- Disturbance in sexual arousal
- Libido decreased
- Keratitis
- Nephrolithiasis
- Lacrimal disorder
- Lacrimal structural disorder
- Vaginal discharge
- Breast pain
- Myocardial infarction
- Acute coronary syndrome
- Nausea
- Neurosis
- Pneumonia
- Hyperacusis
- Stomatitis
- Mouth ulceration
- Shock
- Loss of consciousness
- Tenosynovitis
- Ulcer
- Urinary incontinence
- Vaginal inflammation
- Vaginal infection
- Vomiting
- Weight decreased
- Urinary retention
- Chills
- Mood swings
- Affect lability
- Migraine
- Musculoskeletal stiffness
- Nuchal rigidity
- Ventricular extrasystoles
- Ventricular bigeminy
- Liver function test abnormal
- Mania
- Eye pain
- Paranoia
- Hyperreflexia
- Dry skin
- Accommodation disorder
- Photosensitivity reaction
- Euphoric mood
- Erectile dysfunction
- Abdominal distension
- Bradycardia
- Coordination abnormal
- Face oedema
- Aggression
- Agranulocytosis
- Anaemia
- Aplastic anaemia
- Aphasia
- Arrhythmia
- Asphyxia
- Mental disorder
- Blepharitis
- Coagulopathy
- Bone disorder
- Bursitis
- Candida infection
- Oral candidiasis
- Cellulitis
- Cerebrovascular disorder
- Chest pain
- Retrosternal pain
- Diabetes mellitus
- Diarrhoea
- Diplopia
- Electric shock
- Eosinophilia
- Toxic epidermal necrolysis
- Grand mal convulsion
- Erythema multiforme
- Stevens-Johnson syndrome
- Eye disorder
- Gastritis
- Gastroenteritis
- Gastrointestinal disorder
- Goitre
- Gout
- Headache
- Cardiac disorder
- Cardiomegaly
- Hepatitis
- Herpes zoster
- Hiccups
- Hypercholesterolaemia
- Hyperlipidaemia
- Salivary gland enlargement
- Hyponatraemia
- Orthostatic hypotension
- Hypothyroidism
- Intestinal obstruction
- Jaundice
- Laryngitis
- Left ventricular failure
- Pulmonary oedema
- Leukopenia
- Hepatic cirrhosis
- Lymphocytosis
- Menorrhagia
- Metrorrhagia
- Hypotonia
- Muscle relaxant therapy
- Myoclonus
- Myositis
- Nervous system disorder
- Nightmare
- Nystagmus
- Otitis media
- Palpitations
- Pancreatitis
- Pancytopenia
- Bone marrow depression
- Petechiae
- Phlebitis
- Pneumothorax
- Polyuria
- Diuresis
- Urine output increased
- Pulmonary embolism
- Seborrhoeic dermatitis
- Convulsion
- Salivary hypersecretion
- Skin ulcer
- Aphthous stomatitis
- Withdrawal syndrome
- Hyperhidrosis
- Sweating increased
- Tachycardia
- Thrombocytopenia
- Embolism
- Embolism venous
- Torsade de pointes
- Urethritis
- Urethritis noninfective
- Urethral disorder
- Urinary tract disorder
- Urticaria
- Angiopathy
- Vascular headache
- Arrhythmia supraventricular
- Ventricular arrhythmia
- Stupor
- Depressed level of consciousness
- Breast engorgement
- Dermatitis bullous
- Blister
- Depressive symptom
- Hepatic function abnormal
- Drug withdrawal syndrome
- Deafness transitory
- Partial transitory deafness
- Tongue discolouration
- Tongue disorder
- Tongue oedema
- Impaired healing
- Skin hypertrophy
- Bone pain
- Blood acid phosphatase increased
- Aspartate aminotransferase increased
- Alanine aminotransferase increased
- Tendon rupture
- Malnutrition
- Skin disorder
- Disturbance in attention
- Gravitational oedema
- Extrasystoles
- Hepatobiliary disease
- Major depression
- Akathisia
- Suicidal ideation
- Lymphadenopathy
- Dementia
- Osteoporotic fracture
- Paraesthesia oral
- Hypoaesthesia oral
- Paralysis
- Orthostatic hypertension
- Serotonin syndrome
- Cerebral ischaemia
- Insomnia
- Parosmia
- Suicidal behaviour
- Breast enlargement
- Ageusia
- Ejaculation disorder
- Amblyopia
- Breast feeding
- Coma
- Infection
- Dysgeusia
- Dyspepsia
- Localised oedema
- Epilepsy
- Flatulence
- Hypersensitivity
- Hypertriglyceridaemia
- Blood triglycerides increased
- Lethargy
- Hypertonia
- Nervousness
- Tension
- Neutropenia
- Pain
- Stinging
- Pharyngitis
- Psychotic disorder
- Restless legs syndrome
- Rhinitis
- Tinnitus
- Generalised oedema
- Fluid retention
- Disorientation
- Memory impairment
- Intraocular pressure increased
- Joint swelling
- Drug tolerance
- Oedema mouth
- Oropharyngeal discomfort
- Oropharyngeal pain
- Dependence
- Prostatomegaly
- Self-injurious ideation
- Hypovolaemia
- Drug dependence
- Acne
- Local swelling
- Blood cholesterol increased
Indications
- Agitation
- Bradypsychic response
- Cerebration impaired
- Confusional state
- Decreased interest
- Depressed mood
- Depressive disorder
- Dizziness
- Dysphoria
- Fatigue
- Feeling guilty
- Hepatic impairment
- Hypersomnia
- Insomnia
- Major depression
- Major depressive disorder, single episode
- Mental disorder
- Suicidal ideation
- Suicide attempt
Subjective effects []
| 0xea / Mirtazapine [] | |
|---|---|
Routes:
| |
| a1ko / Mirtazapine [] | |
|---|---|
Routes:
| |
| emily / Mirtazapine [] | |
|---|---|
Routes:
| |
| magnus / Mirtazapine [] | |
|---|---|
Routes:
| |
| Mere / Mirtazapine [] | |
|---|---|
| nervewing / Mirtazapine [] | |
|---|---|
Experience reports
- "My mirtazapine trip" by actuallyaddie (11 upvotes)
- "first time meeting an online friend u already know we got high as hell" by HistoricalNebula5050 (6 upvotes)
- "atypical counterflip (960mg dxm hbr, 128mg chlorpheniramine, 450mg mirtazapine, thc-p)" by DavidsNails (3 upvotes)
- "high dose mirtazapine (remeron) 210mg" by buncedback (3 upvotes)
- "I tripped on mirtazapine" by actuallyaddie (1 upvotes)
- "750mg DPH + 190mg Mirtazapine + 80mg Cinolazepam + 15mg Zopiclone trip report" by -ZoXoXoZ- (1 upvotes)
Legal status []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 4205, Mirtazapine. Accessed November 22, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4205
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Mirtazapine. UNII: A051Q2099Q. Global Substance Registration System. Accessed November 22, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/A051Q2099Q
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Remeron- mirtazapine tablet, film coated; Remeronsoltab- mirtazapine tablet, orally disintegrating. DailyMed. 4 March 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98ad1917-a094-44f5-a28f-a64a8cfcd887
Mirataz- mirtazapine ointment. DailyMed. 5 April 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ff9fdb7-554f-4f91-8cfc-6d05094384c6
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 10:17:35 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 10:17:31 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 10:17:31 |
| gsrs | ok | 2026-11-20 10:17:34 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014514) | 2026-11-20 10:17:31 |
| kegg | ok | 2026-11-20 10:17:33 |
| pubchem | ok | 2026-11-20 10:17:28 |
| ok | 2026-11-20 10:17:31 | |
| sider | ok | 2026-11-20 10:17:32 |
| structure | ok | 2026-11-20 10:17:31 |
| wikipedia | ok | 2026-11-20 10:17:31 |